Trial Outcomes & Findings for Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) (NCT NCT03852719)

Last Updated: 2025-08-22

Results Overview

Combined response was defined as fulfilment of two conditions simultaneously: Undetectable (\< lower limit of quantification (LLOQ, target not detected)) HDV RNA or decrease by ≥ 2 log10 IU/mL from baseline; and ALT normalization.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

150 participants

Primary outcome timeframe

Week 48

Results posted on

2025-08-22

Participant Flow

Participants were enrolled at study sites in Germany, Italy, Russia, and Sweden.

183 participants were screened.

Participant milestones

Participant milestones
Measure	Delayed Treatment/Bulevirtide 10 mg/Day After an observational period of 48 weeks, participants received bulevirtide 10 mg/day subcutaneous (SC) injection for 96 weeks and were followed for up to 96 weeks (Up to Week 240).	Bulevirtide 2 mg/Day Participants received bulevirtide 2 mg/day SC injection for 144 weeks and were followed for up to 96 weeks (Up to Week 240).	Bulevirtide 10 mg/Day Participants received bulevirtide 10 mg/day SC injection for 144 weeks and were followed for up to 96 weeks (Up to Week 240).
Overall Study STARTED	51	49	50
Overall Study Did Not Receive Bulevirtide	1	0	0
Overall Study COMPLETED	28	28	30
Overall Study NOT COMPLETED	23	21	20

Reasons for withdrawal

Reasons for withdrawal
Measure	Delayed Treatment/Bulevirtide 10 mg/Day After an observational period of 48 weeks, participants received bulevirtide 10 mg/day subcutaneous (SC) injection for 96 weeks and were followed for up to 96 weeks (Up to Week 240).	Bulevirtide 2 mg/Day Participants received bulevirtide 2 mg/day SC injection for 144 weeks and were followed for up to 96 weeks (Up to Week 240).	Bulevirtide 10 mg/Day Participants received bulevirtide 10 mg/day SC injection for 144 weeks and were followed for up to 96 weeks (Up to Week 240).
Overall Study Withdrawal of consent	8	8	9
Overall Study Physician Decision	5	4	1
Overall Study Pregnancy	2	1	0
Overall Study Death	1	0	0
Overall Study Reason not Specified	3	3	5
Overall Study Adverse Event	2	1	4
Overall Study Progressive disease	1	4	1
Overall Study Lost to Follow-up	1	0	0

Baseline Characteristics

Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Delayed Treatment/Bulevirtide 10 mg/Day n=51 Participants After an observational period of 48 weeks, participants received bulevirtide 10 mg/day SC injection for 96 weeks and were followed for up to 96 weeks (Up to Week 240).	Bulevirtide 2 mg/Day n=49 Participants Participants received bulevirtide 2 mg/day SC injection for 144 weeks and were followed for up to 96 weeks (Up to Week 240).	Bulevirtide 10 mg/Day n=50 Participants Participants received bulevirtide 10 mg/day SC injection for 144 weeks and were followed for up to 96 weeks (Up to Week 240).	Total n=150 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Age, Categorical Between 18 and 65 years	51 Participants n=5 Participants	49 Participants n=7 Participants	50 Participants n=5 Participants	150 Participants n=4 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Age, Continuous	41 years STANDARD_DEVIATION 7.5 • n=5 Participants	44 years STANDARD_DEVIATION 9.0 • n=7 Participants	41 years STANDARD_DEVIATION 8.5 • n=5 Participants	42 years STANDARD_DEVIATION 8.4 • n=4 Participants
Sex: Female, Male Female	25 Participants n=5 Participants	19 Participants n=7 Participants	20 Participants n=5 Participants	64 Participants n=4 Participants
Sex: Female, Male Male	26 Participants n=5 Participants	30 Participants n=7 Participants	30 Participants n=5 Participants	86 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Asian	11 Participants n=5 Participants	8 Participants n=7 Participants	6 Participants n=5 Participants	25 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants
Race (NIH/OMB) White	40 Participants n=5 Participants	41 Participants n=7 Participants	43 Participants n=5 Participants	124 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Region of Enrollment Germany	7 Participants n=5 Participants	6 Participants n=7 Participants	14 Participants n=5 Participants	27 Participants n=4 Participants
Region of Enrollment Italy	7 Participants n=5 Participants	11 Participants n=7 Participants	6 Participants n=5 Participants	24 Participants n=4 Participants
Region of Enrollment Russia	29 Participants n=5 Participants	28 Participants n=7 Participants	28 Participants n=5 Participants	85 Participants n=4 Participants
Region of Enrollment Sweden	8 Participants n=5 Participants	4 Participants n=7 Participants	2 Participants n=5 Participants	14 Participants n=4 Participants
Hepatitis Delta Virus (HDV) Ribonucleic Acid (RNA)	5.08 log10 IU/mL STANDARD_DEVIATION 1.358 • n=5 Participants	5.10 log10 IU/mL STANDARD_DEVIATION 1.194 • n=7 Participants	4.96 log10 IU/mL STANDARD_DEVIATION 1.461 • n=5 Participants	5.04 log10 IU/mL STANDARD_DEVIATION 1.336 • n=4 Participants
Liver stiffness	15.3 kPa STANDARD_DEVIATION 8.95 • n=5 Participants	14.0 kPa STANDARD_DEVIATION 8.19 • n=7 Participants	14.8 kPa STANDARD_DEVIATION 9.26 • n=5 Participants	14.7 kPa STANDARD_DEVIATION 8.77 • n=4 Participants

PRIMARY outcome

Timeframe: Week 48

Population: The Full Analysis Set included participants randomized to delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. Participants were grouped according to randomized treatment. The arm titles and descriptions in this outcome measure are entered accordingly.

Outcome measures

Outcome measures
Measure	Delayed Treatment n=51 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=49 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=50 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Percentage of Participants With Combined Response at Week 48	2.0 percentage of participants Interval 0.0 to 10.4	44.9 percentage of participants Interval 30.7 to 59.8	48.0 percentage of participants Interval 33.7 to 62.6	—

SECONDARY outcome

Timeframe: Week 48

Population: Participants in the Full Analysis Set were analyzed. Participants were grouped according to randomized treatment. The arm titles and descriptions in this outcome measure are entered accordingly.

Undetectable HDV RNA at Week 48 means undetectable (\< LLOQ, target not detected) HDV RNA at Week 48.

Outcome measures

Outcome measures
Measure	Delayed Treatment n=51 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=49 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=50 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Percentage of Participants With Undetectable HDV RNA at Week 48	0 percentage of participants Interval 0.0 to 7.0	12.2 percentage of participants Interval 4.6 to 24.8	20.0 percentage of participants Interval 10.0 to 33.7	—

SECONDARY outcome

Timeframe: Week 48

ALT normalization was defined as an ALT value within the normal range, based on the central laboratories \[Russian sites: ≤ 31 U/L for females and ≤ 41 U/L for males; all other sites: ≤ 34 U/L for females and ≤ 49 U/L for males\])

Outcome measures

Outcome measures
Measure	Delayed Treatment n=51 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=49 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=50 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48	11.8 percentage of participants Interval 4.4 to 23.9	51.0 percentage of participants Interval 36.3 to 65.6	56.0 percentage of participants Interval 41.3 to 70.0	—

SECONDARY outcome

Timeframe: Baseline (Baseline for Delayed Treatment/Bulevirtide 10 mg/day is reset at Week 48), Week 48

Population: Participants in the Full Analysis Set with available data were analyzed. Data is reported separately for changes from Baseline at Week 48 for the Delayed Treatment arm and for Delayed Treatment/Bulevirtide 10 mg/day arm after 48 weeks of bulevirtide 10 mg treatment. Participants were grouped according to randomized treatment and study design. The arm titles and descriptions in the outcome measure are entered accordingly.

ANCOVA was used for analysis.

Outcome measures

Outcome measures
Measure	Delayed Treatment n=46 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=48 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=42 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day n=48 Participants Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 48	0.87 kPa Interval -0.79 to 2.53	-3.06 kPa Interval -4.67 to -1.45	-3.16 kPa Interval -4.88 to -1.43	-3.36 kPa Interval -4.6 to -2.12

SECONDARY outcome

Timeframe: Baseline (Baseline for Delayed Treatment/Bulevirtide 10 mg/day is reset at Week 48), Week 96

Population: Participants from Full Analysis Set with available data were analyzed. Participants were grouped according to randomized treatment and study design. The arm titles and descriptions in the outcome measure are entered accordingly.

Mixed model for repeated measurements (MMRM) was used for analysis.

Outcome measures

Outcome measures
Measure	Delayed Treatment n=47 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=47 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=48 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 96	-4.31 kPa Interval -5.54 to -3.08	-4.88 kPa Interval -6.11 to -3.65	-4.20 kPa Interval -5.41 to -2.98	—

SECONDARY outcome

Timeframe: Baseline, Week 144

MMRM was used for analysis.

Outcome measures

Outcome measures
Measure	Delayed Treatment n=45 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=43 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 144	-5.24 kPa Interval -6.85 to -3.63	-4.03 kPa Interval -5.67 to -2.4	—	—

SECONDARY outcome

Timeframe: Baseline (Baseline for Delayed Treatment/Bulevirtide 10 mg/day is reset at Week 48), Week 192

MMRM was used for analysis.

Outcome measures

Outcome measures
Measure	Delayed Treatment n=35 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=34 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=35 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 192	-3.74 kPa Interval -5.28 to -2.2	-3.70 kPa Interval -5.27 to -2.14	-1.91 kPa Interval -3.49 to -0.34	—

SECONDARY outcome

Timeframe: Baseline (Baseline for Delayed Treatment/Bulevirtide 10 mg/day is reset at Week 48), Week 240

MMRM was used for analysis.

Outcome measures

Outcome measures
Measure	Delayed Treatment n=28 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=29 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=28 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Change From Baseline in Liver Stiffness, as Measured by Elastography at Week 240	-1.20 kPa Interval -3.71 to 1.31	-3.31 kPa Interval -5.78 to -0.84	-3.59 kPa Interval -6.14 to -1.04	—

SECONDARY outcome

Timeframe: Week 168

Population: Participants in the Full Analysis Set were analyzed. Participants were grouped according to randomized treatment and study design. The arm titles and descriptions in the outcome measure are entered accordingly.

Undetectable HDV RNA 24 Weeks after Scheduled End of Treatment means undetectable (\< LLOQ, target not detected) HDV RNA at Week 168

Outcome measures

Outcome measures
Measure	Delayed Treatment n=49 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=50 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=50 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Percentage of Participants With Undetectable HDV RNA 24 Weeks After Scheduled End of Treatment (Sustained Virological Response)	18.4 percentage of participants Interval 8.8 to 32.0	26.0 percentage of participants Interval 14.6 to 40.3	18.0 percentage of participants Interval 8.6 to 31.4	—

SECONDARY outcome

Timeframe: Week 192

Undetectable HDV RNA 48 Weeks after Scheduled End of Treatment means undetectable (\< LLOQ, target not detected) HDV RNA at Week 192

Outcome measures

Outcome measures
Measure	Delayed Treatment n=49 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=50 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=50 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Percentage of Participants With Undetectable HDV RNA 48 Weeks After Scheduled End of Treatment (Sustained Virological Response)	16.3 percentage of participants Interval 7.3 to 29.7	24.0 percentage of participants Interval 13.1 to 38.2	16.0 percentage of participants Interval 7.2 to 29.1	—

SECONDARY outcome

Timeframe: Delayed Treatment/Bulevirtide 10 mg/day arm: Week 48 up to Week 144; Bulevirtide 2mg/day and 10 mg/day arms: First dose date up to Week 144

Population: Participants in the SAS were analyzed. The SAS included all participants who were randomized into the study and took at least 1 dose of bulevirtide study drug, or who were randomized to the delayed treatment group. Participants were grouped according to actual treatment received for time points Week 0 to 144. The arm titles and descriptions in this outcome measure are entered accordingly.

An AE was defined as any untoward medical occurrence in a participant administered study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to the study drug.

Outcome measures

Outcome measures
Measure	Delayed Treatment n=49 Participants Observation period of 48 weeks.	Bulevirtide 2 mg/Day n=50 Participants Participants received bulevirtide 2 mg/day SC injection for 48 weeks.	Bulevirtide 10 mg/Day n=50 Participants Participants received bulevirtide 10 mg/day SC injection for 48 weeks.	Delayed Treatment / /Bulevirtide 10 mg/Day Participants received Bulevirtide 10 mg/Day SC for 48 weeks after an observation period of 48 weeks.
Percentage of Participants Who Prematurely Discontinued Study Drug Due to an Adverse Event (AE) by Week 144	0 percentage of participants	0 percentage of participants	0 percentage of participants	—

Adverse Events

Delayed Treatment (Baseline to Week 48)

Serious events: 1 serious events

Other events: 30 other events

Deaths: 0 deaths

Bulevirtide 2 mg/Day (Baseline to Week 48)

Serious events: 2 serious events

Other events: 35 other events

Deaths: 0 deaths

Bulevirtide 10 mg/Day (Baseline to Week 48)

Serious events: 1 serious events

Other events: 41 other events

Deaths: 0 deaths

Bulevirtide 2 mg/Day (Baseline to Week 144)

Serious events: 3 serious events

Other events: 44 other events

Deaths: 0 deaths

Bulevirtide 10 mg/Day (Baseline to Week 144)

Serious events: 6 serious events

Other events: 46 other events

Deaths: 0 deaths

Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144)

Serious events: 3 serious events

Other events: 41 other events

Deaths: 1 deaths

Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240))

Serious events: 7 serious events

Other events: 31 other events

Deaths: 0 deaths

Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240)

Serious events: 7 serious events

Other events: 33 other events

Deaths: 0 deaths

Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240)

Serious events: 8 serious events

Other events: 34 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Delayed Treatment (Baseline to Week 48) n=51 participants at risk Observation for 48 weeks.	Bulevirtide 2 mg/Day (Baseline to Week 48) n=49 participants at risk Bulevirtide 2 mg/day SC for 48 weeks.	Bulevirtide 10 mg/Day (Baseline to Week 48) n=50 participants at risk Bulevirtide 10 mg/day SC for 48 weeks.	Bulevirtide 2 mg/Day (Baseline to Week 144) n=49 participants at risk Participants received bulevirtide 2 mg/day SC for 144 weeks.	Bulevirtide 10 mg/Day (Baseline to Week 144) n=50 participants at risk Participants received bulevirtide 10 mg/day SC for 144 weeks.	Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) n=50 participants at risk After an observational period of 48 weeks, participants received bulevirtide 10 mg/day SC for 96 weeks (Up to Week 144).	Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) n=46 participants at risk After 144 weeks of treatment with bulevirtide 2 mg/day SC, participants were followed for up to 96 weeks (Up to Week 240).	Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) n=47 participants at risk After 144 weeks of treatment with bulevirtide 10 mg/day SC, participants were followed for up to 96 weeks (Up to Week 240).	Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) n=49 participants at risk After 96 weeks of treatment (Up to Week 144) with bulevirtide 10 mg/day SC, participants were followed for up to 96 weeks (Up to Week 240).
Blood and lymphatic system disorders Anaemia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Gastrointestinal disorders Oesophageal varices haemorrhage	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Gastrointestinal disorders Varices oesophageal	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Hepatobiliary disorders Cholelithiasis	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Hepatobiliary disorders Hepatic fibrosis	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Hepatobiliary disorders Hepatitis	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Hepatobiliary disorders Hepatitis acute	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Hepatobiliary disorders Liver injury	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Chronic hepatitis B	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Coronavirus pneumonia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Covid-19	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Covid-19 pneumonia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Hepatitis D	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.7% 4/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.5% 4/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Hepatitis E	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Urinary tract infection	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Yersinia infection	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Alanine aminotransferase increased	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Transaminases increased	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatocellular carcinoma	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Phyllodes tumour	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Plasma cell myeloma	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Nervous system disorders Facial paralysis	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Nervous system disorders Headache	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Nervous system disorders Hemiparesis	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Psychiatric disorders Depression	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Renal and urinary disorders Urinary retention	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.

Other adverse events

Other adverse events
Measure	Delayed Treatment (Baseline to Week 48) n=51 participants at risk Observation for 48 weeks.	Bulevirtide 2 mg/Day (Baseline to Week 48) n=49 participants at risk Bulevirtide 2 mg/day SC for 48 weeks.	Bulevirtide 10 mg/Day (Baseline to Week 48) n=50 participants at risk Bulevirtide 10 mg/day SC for 48 weeks.	Bulevirtide 2 mg/Day (Baseline to Week 144) n=49 participants at risk Participants received bulevirtide 2 mg/day SC for 144 weeks.	Bulevirtide 10 mg/Day (Baseline to Week 144) n=50 participants at risk Participants received bulevirtide 10 mg/day SC for 144 weeks.	Delayed Treatment/Bulevirtide 10 mg/Day (Week 48 to Week 144) n=50 participants at risk After an observational period of 48 weeks, participants received bulevirtide 10 mg/day SC for 96 weeks (Up to Week 144).	Bulevirtide 2 mg/Day (After EOT (>Week 144 up to Week 240)) n=46 participants at risk After 144 weeks of treatment with bulevirtide 2 mg/day SC, participants were followed for up to 96 weeks (Up to Week 240).	Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) n=47 participants at risk After 144 weeks of treatment with bulevirtide 10 mg/day SC, participants were followed for up to 96 weeks (Up to Week 240).	Delayed Treatment/Bulevirtide 10 mg/Day (After EOT (>Week 144 up to Week 240) n=49 participants at risk After 96 weeks of treatment (Up to Week 144) with bulevirtide 10 mg/day SC, participants were followed for up to 96 weeks (Up to Week 240).
Blood and lymphatic system disorders Anaemia	5.9% 3/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Blood and lymphatic system disorders Eosinophilia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Blood and lymphatic system disorders Leukopenia	19.6% 10/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.3% 7/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	20.4% 10/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	18.0% 9/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.0% 7/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.5% 4/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Blood and lymphatic system disorders Lymphopenia	7.8% 4/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.2% 4/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	16.3% 8/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	12.0% 6/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.5% 3/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.5% 4/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.3% 7/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Blood and lymphatic system disorders Neutropenia	5.9% 3/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	16.3% 8/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	20.0% 10/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.5% 3/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.5% 4/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Blood and lymphatic system disorders Thrombocytopenia	15.7% 8/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	20.4% 10/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	16.0% 8/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.0% 7/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	13.0% 6/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.6% 5/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.3% 7/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Cardiac disorders Bradycardia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Cardiac disorders Sinus bradycardia	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Gastrointestinal disorders Abdominal pain	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Gastrointestinal disorders Abdominal pain upper	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Gastrointestinal disorders Diarrhoea	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Gastrointestinal disorders Gastritis	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Gastrointestinal disorders Nausea	3.9% 2/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	12.0% 6/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
General disorders Asthenia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.5% 3/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.5% 4/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.2% 4/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
General disorders Fatigue	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.0% 7/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.3% 7/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	18.0% 9/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.6% 5/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.2% 4/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
General disorders Injection site erythema	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
General disorders Injection site pruritus	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
General disorders Injection site reaction	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	12.0% 6/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
General disorders Injection site swelling	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
General disorders Oedema peripheral	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
General disorders Pyrexia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Hepatobiliary disorders Hepatic fibrosis	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.9% 5/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.5% 4/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.2% 4/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Covid-19	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	16.0% 8/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.0% 5/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Nasopharyngitis	3.9% 2/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.2% 4/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Infections and infestations Urinary tract infection	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	12.0% 6/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Activated partial thromboplastin time prolonged	3.9% 2/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.4% 3/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Alanine aminotransferase increased	7.8% 4/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	10.2% 5/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	41.3% 19/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	23.4% 11/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	36.7% 18/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Alpha-2 macroglobulin increased	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.2% 4/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.4% 3/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	12.2% 6/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Amylase increased	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Aspartate aminotransferase increased	5.9% 3/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	37.0% 17/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	23.4% 11/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	30.6% 15/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Bilirubin conjugated increased	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.7% 4/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Blood bilirubin increased	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Gamma-glutamyltransferase increased	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	17.4% 8/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.5% 4/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Hepatitis D RNA positive	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.5% 4/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Lipase increased	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Transaminases increased	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.9% 7/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Investigations Weight decreased	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.5% 3/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Metabolism and nutrition disorders Vitamin D deficiency	25.5% 13/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.3% 7/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.0% 7/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	44.9% 22/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	38.0% 19/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	28.0% 14/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	13.0% 6/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.9% 7/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.3% 7/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	12.2% 6/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	16.0% 8/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Musculoskeletal and connective tissue disorders Osteopenia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Nervous system disorders Dizziness	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Nervous system disorders Headache	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	18.4% 9/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	20.0% 10/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	20.4% 10/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	24.0% 12/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.0% 7/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.1% 1/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Psychiatric disorders Sleep disorder	2.0% 1/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.3% 2/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Renal and urinary disorders Proteinuria	3.9% 2/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.2% 4/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.1% 2/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	12.2% 6/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	14.0% 7/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	12.2% 6/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	16.0% 8/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.2% 1/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.4% 3/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.
Vascular disorders Hypertension	0.00% 0/51 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.0% 3/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	6.1% 3/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	8.0% 4/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	4.0% 2/50 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/46 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	0.00% 0/47 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.	2.0% 1/49 • All-Cause Mortality: Up to Week 240; Adverse Events: Up to Week 48 (first 3 arms); Up to Week 144 (arms 4 and 5); Up to Weeks 48-144 (arm 6); >Week 144 up to Week 240 (arms 7-9). Adverse Event: SAS included all participants randomized (posttreatment SAS required >=1 measurement after EOT) delayed treatment arm or randomized to bulevirtide and received bulevirtide at least once after randomization. All-cause mortality: Randomized Set included all enrolled and randomized participants. Participants were grouped according to actual treatment received for time points Week (Wk) 0 to 48, 0 to 144, Wk 48 to 144 and by last treatment received after Wk 144, up to Wk 240. The arm titles and descriptions in this section are entered accordingly. Actual treatment received is defined as randomized treatment except for participants who received treatment that differs from randomized treatment for the entire treatment duration.

Additional Information

Gilead Clinical Study Information Center

Gilead Sciences

Phone: 1-833-445-3230 (GILEAD-0)

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: * The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or * The study has been completed at all study sites for at least 2 years
Publication restrictions are in place

Restriction type: OTHER